EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Short‐Term Safety and Adverse Event Risk Profiles for SARS‐CoV‐2 Booster Vaccine Doses in Australian Adults: A Survey Study

Evelyn Tay iD, Michael Dymock iD, Lucy Dawes iD, Lucy Deng iD, Thuy Nguyen iD, Alan Leeb, Julie A Marsh, Nicholas Wood, Kristine Macartney iD, Thomas L Snelling

Medical Journal of Australia · 2026-06 · 224 (6)

DOI: 10.5694/mja2.70227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Australia, online erschienen am 16.06.2026. Verfasst von Evelyn Tay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Immunization, Secondary. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Health, Disability and Ageing, Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study quantifies the short‐term risk profiles of seven severe acute respiratory syndrome coronavirus 2 virus (SARS‐CoV‐2) vaccines—Comirnaty Bivalent BA.1, Comirnaty Bivalent BA.4‐5, Comirnaty XBB.1.5, Spikevax Bivalent BA.1, Spikevax Bivalent BA.4‐5, Spikevax XBB.1.5 and Nuvaxovid—administered as booster doses in Australia.

Design

This is a survey study using data collected from online surveys sent via AusVaxSafety, the Australian active vaccine safety surveillance system, 3 days post‐vaccination, soliciting reports of adverse events following vaccination. Participants and Setting Individuals 18 years and older who received a SARS‐CoV‐2 vaccine booster at an AusVaxSafety vaccine surveillance site between 1 January 2023 and 31 August 2024. Main Outcome Measures Bayesian logistic regression was used to estimate risk of reported adverse events, seeking medical advice and impact on daily activities.

Results

Of 197,476 respondents, 59,089 (29.9%) reported at least one adverse event, of which the most commonly reported symptoms were injection site reaction (23.8% [46,988/197,476]) and fatigue (19.4% [38,352/197,476]). Symptom resolution was reported by 69.9% (41,299/59,089) by day 3 and 5.6% (11,006/197,476) reported any time lost from daily activities. The unadjusted proportion of respondents who sought medical advice was higher in those who received Spikevax XBB.1.5 (1.2% [212/17,551]) than the other vaccines (0.5% [379/69,493] to 0.7% [147/20,271]), but the modelled, adjusted mean risk of medical advice was similar (< 2.5%) across subgroups for vaccine brands, co‐administered vaccines, medical conditions, age, sex and Indigenous status. The modelled risk of any adverse event at age 40 years ranged from 35.2% (95% credible interval [CrI], 32.2%–38.5%) for men who had received Comirnaty XBB.1.5 to 75.5% (95% CrI, 71.9%–78.8%) for women who had received Spikevax XBB.1.5. At age 80 years, this risk was lowest across all vaccines, ranging from 12.0% (95% CrI, 11.2%–13.0%) for men who had received Comirnaty BA4‐5 to 36.7% (95% CrI, 34.6%–38.7%) for women who had received Spikevax XBB.1.5.

Conclusions

The results of this study confirm the short‐term safety and low impact on daily living of SARS‐CoV‐2 booster vaccine administration to Australian adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19Immunization, SecondaryHumansAustraliaFemaleMaleAdultMiddle AgedAgedSARS-CoV-2Surveys and QuestionnairesYoung AdultAdolescentBayes Theorem

Stichwörter der Autor:innen

SARS‐CoV‐2vaccine safetyvaccines

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
  • Perth's Children's Hospital, The Kids Research Institute Australia, Nedlands, Western Australia, Australia.
  • Kids Research National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia.
  • SmartVax, Ballajura, Western Australia, Australia.
  • Illawarra Medical Centre, Ballajura, Western Australia, Australia.
  • Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Evelyn Tay, Michael Dymock, Lucy Dawes, Lucy Deng, Thuy Nguyen, Kristine Macartney

Förderung

  • Department of Health, Disability and Ageing, Australian Government

Zitieren

APA

Tay, E., Dymock, M., Dawes, L., Deng, L., Nguyen, T., Leeb, A., Marsh, J. A., Wood, N., Macartney, K., & Snelling, T. L. (2026). Short‐Term Safety and Adverse Event Risk Profiles for SARS‐CoV‐2 Booster Vaccine Doses in Australian Adults: A Survey Study. Medical Journal of Australia, 224(6). https://doi.org/10.5694/mja2.70227

Vancouver

Tay E, Dymock M, Dawes L, Deng L, Nguyen T, Leeb A, et al. Short‐Term Safety and Adverse Event Risk Profiles for SARS‐CoV‐2 Booster Vaccine Doses in Australian Adults: A Survey Study. Medical Journal of Australia. 2026;224(6). doi:10.5694/mja2.70227

BibTeX
@article{Tay2026,
  author = {Tay, Evelyn and Dymock, Michael and Dawes, Lucy and Deng, Lucy and Nguyen, Thuy and Leeb, Alan and Marsh, Julie A and Wood, Nicholas and Macartney, Kristine and Snelling, Thomas L},
  title = {Short‐Term Safety and Adverse Event Risk Profiles for SARS‐CoV‐2 Booster Vaccine Doses in Australian Adults: A Survey Study},
  journal = {Medical Journal of Australia},
  year = {2026},
  volume = {224},
  number = {6},
  doi = {10.5694/mja2.70227}
}
Kostenlos starten →